

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 May 2020 (22.05.2020)



(10) International Publication Number
WO 2020/102730 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 401/14 (2006.01)

(21) International Application Number:

PCT/US2019/061815

(22) International Filing Date:

15 November 2019 (15.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/768,802 16 November 2018 (16.11.2018) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: PARSONS, Andrew Thomas; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, California 91320-1799 (US). COCHRAN, Brian McNeil; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, California 91320-1799 (US). POWAZINIK, IV, William; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, California 91320-1799 (US). CA-PORINI, Marc Anthony; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: REIDY, Joseph F.; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

WO 2020/102730 A1

(54) Title: IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND

(57) Abstract: The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure (I), useful for the synthesis of compounds that target KRAS G12C mutations, such as (II).